Status: Recruiting
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Participants needed: 60
Trial details
Phase: Phase 2Age: 6-65Biological sex: AllType: InterventionalSponsor: Children's Hospital of PhiladelphiaUpdated: Jun 22, 2026Locations: 1
Eligibility criteria
Males or females age 6 months to 65 years. [+4]
Parents/guardians or subjects who, in the opinion of the Investigator, may be no... [+4]